Exploring the impact of osteoprotegerin on osteoclast and precursor fusion: Mechanisms and modulation by ATP
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Osteoprotegerin (OPG) inhibits osteoclast fusion and differentiation by affecting key molecules and their locations. Adenosine triphosphate (ATP) can mitigate OPG's inhibitory effects, suggesting a role for ATP signaling.
Area Of Science
- Cell Biology
- Bone Biology
- Biochemistry
Background
- Osteoclast differentiation is crucial for bone resorption and involves cell fusion.
- Osteoprotegerin (OPG) is a known inhibitor of osteoclast differentiation, but its precise role in cell fusion remains unclear.
- Understanding OPG's mechanisms in osteoclast fusion is vital for addressing bone metabolism disorders.
Purpose Of The Study
- To investigate the effects of Osteoprotegerin (OPG) on osteoclast and precursor fusion.
- To elucidate the molecular mechanisms by which OPG influences osteoclast fusion.
- To explore the potential role of Adenosine Triphosphate (ATP) in modulating OPG's effects on osteoclast fusion.
Main Methods
- Osteoclasts and their precursors were treated with OPG, alone or in combination with ATP.
- Quantitative analysis of osteoclast number, area, and motility was performed.
- Expression and subcellular localization of fusion-related molecules (CD44, CD47, DC-STAMP, ATP6V0D2) and Connexin43 were assessed.
- Western blotting was used to analyze phosphorylated forms of Connexin43.
Main Results
- OPG significantly reduced osteoclast number, area, and motility, while having minimal effect on precursor motility.
- OPG downregulated fusion-related molecules in osteoclasts and precursors, with distinct effects on each cell type.
- OPG disrupted the subcellular localization of key fusion molecules and Connexin43 in both osteoclasts and precursors.
- ATP treatment mitigated the inhibitory effects of OPG on osteoclast fusion and related molecular changes.
Conclusions
- OPG inhibits osteoclast multinucleated fusion and mononuclear precursor fusion through distinct molecular mechanisms.
- OPG affects the expression and localization of critical fusion proteins, including CD44, CD47, DC-STAMP, ATP6V0D2, and Connexin43.
- ATP signaling pathway may play a regulatory role in mitigating OPG's inhibitory effects on osteoclast fusion, offering potential therapeutic insights.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Hormonal Control of Bone Remodeling
Parathyroid hormone (PTH) maintains homeostatic control of blood calcium levels by regulating bone resorption. PTH is...
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...